The global vaginal microbiome diagnostics market size was valued at USD 579.4 million in 2025 and is projected to grow from USD 659.6 million in 2026 to USD 1.72 billion by 2033, at a CAGR of 14.7% from 2026 to 2033. North America dominated the market, accounting for the revenue share of 40.9% in 2025. Market growth is primarily driven by the high burden of bacterial vaginosis and vaginal dysbiosis, increasing adoption of molecular diagnostic technologies, and growing demand for accurate and comprehensive vaginal microbiome profiling.
Regulatory considerations become particularly important as companies expand from centralized laboratory testing toward decentralized molecular diagnostics, where usability and workflow performance must also be demonstrated.
Product expansion is strengthening the global market as companies broaden testing beyond pathogen identification to include the characterization of beneficial and dysbiosis-associated microorganisms. Newer solutions increasingly assess Lactobacillus species alongside organisms associated with bacterial vaginosis, candidiasis, mixed infections, and recurrent vaginal conditions, enabling a more comprehensive evaluation of vaginal microbial composition. Quantitative molecular methods and sequencing-based approaches can further expand the information obtained from a single specimen and support a more personalized interpretation of vaginal health.
For instance, in July 2026, CirrusDx launched LacP, a Lactobacillus panel designed to identify and quantify key Lactobacillus species the support a healthy vaginal environment. The expansion toward measuring protective microbial populations represents an important evolution beyond conventional pathogen-centered testing and can support the evaluation of dysbiosis and recurrent symptoms. Continued expansion of microbial targets, quantitative capabilities, and clinically interpreted results is expected to broaden the range of addressable applications for vaginal microbiome diagnostics.
Regional expansion is creating growth opportunities in the vaginal microbiome diagnostics industry as molecular testing, self-collection, digital healthcare, and specialized women's-health services increase access to vaginal microbiome assessment. North America benefits from an established molecular diagnostic infrastructure and reference laboratory networks, while Europe and the Asia Pacific offer expansion potential through improvements in molecular capabilities, reproductive health services, and the adoption of personalized diagnostics. Partnerships that connect microbiome testing with virtual clinical care can further increase access without requiring patients to follow exclusively conventional in-person diagnostic pathways. For instance, in June 2025, Organon and Evvy announced a U.S. collaboration integrating Evvy's vaginal microbiome testing and clinical-care platform with access to XACIATO for eligible patients diagnosed with bacterial vaginosis.
Market Characteristics & Concentration
Regulations have a significant impact on the market by influencing product development, clinical validation, commercialization, and adoption across healthcare settings. In the U.S., nucleic acid detection systems intended to aid the diagnosis of vaginitis and bacterial vaginosis are regulated by the FDA as Class II in vitro diagnostic devices, requiring manufacturers to demonstrate appropriate analytical and clinical performance, along with applicable quality and labeling requirements.Regulatory considerations become particularly important as companies expand from centralized laboratory testing toward decentralized molecular diagnostics, where usability and workflow performance must also be demonstrated.
Product expansion is strengthening the global market as companies broaden testing beyond pathogen identification to include the characterization of beneficial and dysbiosis-associated microorganisms. Newer solutions increasingly assess Lactobacillus species alongside organisms associated with bacterial vaginosis, candidiasis, mixed infections, and recurrent vaginal conditions, enabling a more comprehensive evaluation of vaginal microbial composition. Quantitative molecular methods and sequencing-based approaches can further expand the information obtained from a single specimen and support a more personalized interpretation of vaginal health.
For instance, in July 2026, CirrusDx launched LacP, a Lactobacillus panel designed to identify and quantify key Lactobacillus species the support a healthy vaginal environment. The expansion toward measuring protective microbial populations represents an important evolution beyond conventional pathogen-centered testing and can support the evaluation of dysbiosis and recurrent symptoms. Continued expansion of microbial targets, quantitative capabilities, and clinically interpreted results is expected to broaden the range of addressable applications for vaginal microbiome diagnostics.
Regional expansion is creating growth opportunities in the vaginal microbiome diagnostics industry as molecular testing, self-collection, digital healthcare, and specialized women's-health services increase access to vaginal microbiome assessment. North America benefits from an established molecular diagnostic infrastructure and reference laboratory networks, while Europe and the Asia Pacific offer expansion potential through improvements in molecular capabilities, reproductive health services, and the adoption of personalized diagnostics. Partnerships that connect microbiome testing with virtual clinical care can further increase access without requiring patients to follow exclusively conventional in-person diagnostic pathways. For instance, in June 2025, Organon and Evvy announced a U.S. collaboration integrating Evvy's vaginal microbiome testing and clinical-care platform with access to XACIATO for eligible patients diagnosed with bacterial vaginosis.
Global Vaginal Microbiome Diagnostics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global vaginal microbiome diagnostics market report based on the product, technology, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Reagents & Consumables
- Software & Services
Technology Outlook (Revenue, USD Million, 2021 - 2033)
- PCR/qPCR & Other Targeted Nucleic Acid Amplification
- Next-Generation Sequencing
- Other Technologies
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Bacterial Vaginosis & Vaginal Dysbiosis
- Vulvovaginal Candidiasis
- Mixed & Recurrent Vaginitis
- Fertility, Pregnancy & Reproductive Health
- Menopause & Genitourinary Syndrome
- Other Applications
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic & Reference Laboratories
- Fertility & Reproductive Health Centers
- Direct-to-Consumer
- Other End-uses
Regional Outlook (Revenue, USD Million; 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Vaginal Microbiome Diagnostics Market Variables, Trends & Scope
Chapter 4. Global Vaginal Microbiome Diagnostics Market: Product Estimates & Trend Analysis
Chapter 5. Global Vaginal Microbiome Diagnostics Market: Technology Estimates & Trend Analysis
Chapter 6. Global Vaginal Microbiome Diagnostics Market: Application Estimates & Trend Analysis
Chapter 7. Global Vaginal Microbiome Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 8. Vaginal Microbiome Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Hologic, Inc.
- Quest Diagnostics Incorporated
- Labcorp Holdings Inc.
- Cepheid / Danaher Corporation
- Becton, Dickinson and Company
- Seegene, Inc.
- Mayo Clinic Laboratories
- F. Hoffmann-La Roche Ltd.
- Evvy
- Juno Bio
